{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:12:52Z","timestamp":1752282772114,"version":"3.41.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Immuncheckpointinhibitoren (ICI) werden bei multiplen malignen Erkrankungen erfolgreich eingesetzt. Zum Nebenwirkungsspektrum geh\u00f6ren neben dermatologischen, endokrinologischen, gastrointestinalen und hepatischen auch selten neurologische Nebenwirkungen des zentralen und h\u00e4ufiger des peripheren Nervensystems. Vorbestehende neurologische Erkrankungen k\u00f6nnen sich verschlechtern. Das bilateral auftretende Karpaltunnelsyndrom (KTS) tritt selten auf. Im vorliegenden Fall kam es bei einem 83-j\u00e4hrigen Patienten mit malignem Melanom (MM) im Stadium\u00a0IIIC nach 5 adjuvanten Therapiezyklen mit Pembrolizumab 200\u00a0mg zu Schmerzen, Schwellungen und Par\u00e4sthesien in beiden H\u00e4nden. Nach Diagnostik eines beidseitigen KTS wurde eine Prednisolon-Sto\u00dftherapie durchgef\u00fchrt und auf eine Erhaltungsdosis von 20\u00a0mg p.o. reduziert. Trotz notwendiger Eskalation der ICI-Therapie auf Ipilimumab\/Nivolumab bei Progress des MM konnte unter begleitender Prednisolon-Therapie und Physiotherapie das KTS verbessert werden.<\/jats:p>","DOI":"10.1007\/s00105-025-05480-6","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:40:25Z","timestamp":1746193225000},"page":"377-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bilaterales Karpaltunnelsyndrom bei einem Patienten mit malignem Melanom unter adjuvanter Pembrolizumab-Therapie","Bilateral carpal tunnel syndrome in a patient with malignant melanoma undergoing adjuvant pembrolizumab therapy"],"prefix":"10.1007","volume":"76","author":[{"given":"S.","family":"Weyer-Fahlbusch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sandersfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ritthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"D\u00fccker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Susok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Gambichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"1","key":"5480_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41572-024-00521-1","volume":"10","author":"LB Dahlin","year":"2024","unstructured":"Dahlin\u00a0LB, Zimmerman\u00a0M, Calcagni\u00a0M, Hundepool\u00a0CA, van Alfen\u00a0N, Chung\u00a0KC (2024) Carpal tunnel syndrome. Nat Rev Dis Primers 10(1):37","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"5480_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1177\/1078155220950430","volume":"27","author":"L Eisenbud","year":"2021","unstructured":"Eisenbud\u00a0L, Ejadi\u00a0S, Mar\u00a0N (2021) Development of carpal tunnel syndrome in association with checkpoint inhibitors. J\u00a0Oncol Pharm Pract 27(3):764\u2013765","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"5480_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/bjd.18358","volume":"182","author":"T Gambichler","year":"2020","unstructured":"Gambichler\u00a0T, Susok\u00a0L, Fels\u00a0M, Schneider-Gold\u00a0C, Hof Zum Berge\u00a0F, Stockfleth\u00a0E, Ayzenberg\u00a0I (2020) Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a\u00a0female patient with melanoma. Br J Dermatol 182(1):246\u2013247","journal-title":"Br J Dermatol"},{"issue":"6","key":"5480_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2217\/imt-2023-0273","volume":"16","author":"JC Hunting","year":"2024","unstructured":"Hunting\u00a0JC, Faucheux\u00a0AT, Price\u00a0SN, Elko\u00a0CA, Quattlebaum\u00a0A, Bloomer\u00a0C, Olson\u00a0E, Petty\u00a0WJ, Lycan\u00a0TW Jr. (2024) Patterns of neurological adverse events among a\u00a0retrospective cohort of patients receiving immune checkpoint inhibitors. Immunotherapy 16(6):381\u2013390","journal-title":"Immunotherapy"},{"issue":"3","key":"5480_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/CJI.0000000000000344","volume":"44","author":"D Lechevalier","year":"2021","unstructured":"Lechevalier\u00a0D, Denis\u00a0D, Le Corre\u00a0Y, Heidelberger\u00a0V, Brunet-Possenti\u00a0F, Longvert\u00a0C, Piot\u00a0JM, Maillard\u00a0H, Beneton\u00a0N (2021) French Skin Cancer Group. Carpal Tunnel Syndrome: A\u00a0New Adverse Effect of Immune Checkpoint Inhibitors, 11 Cases. J\u00a0Immunother 44(3):122\u2013126","journal-title":"J Immunother"},{"issue":"3","key":"5480_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.21873\/invivo.13589","volume":"38","author":"T Loupret","year":"2024","unstructured":"Loupret\u00a0T, Boisseau\u00a0R, Lopez\u00a0JG, Bertin\u00a0P, Vergne-Salle\u00a0P (2024) Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma. In Vivo 38(3):1451\u20131453","journal-title":"In Vivo"},{"key":"5480_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins\u00a0F, Sofiya\u00a0L, Sykiotis\u00a0GP et\u00a0al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"key":"5480_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/B978-0-12-823912-4.00024-4","volume":"200","author":"JA McCombe","year":"2024","unstructured":"McCombe\u00a0JA, Sechi\u00a0E, Zekeridou\u00a0A (2024) Neurologic manifestations of autoimmunity with immune checkpoint inhibitors. Handb Clin Neurol 200:449\u2013465","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"5480_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2169\/internalmedicine.2221-23","volume":"63","author":"Y Nakayama","year":"2024","unstructured":"Nakayama\u00a0Y, Sawa\u00a0N, Suwabe\u00a0T, Yamanouchi\u00a0M, Ikuma\u00a0D, Mizuno\u00a0H, Hasegawa\u00a0E, Sekine\u00a0A, Oba\u00a0Y, Ishiwata\u00a0K, Wake\u00a0A, Hatano\u00a0M, Kitajima\u00a0I, Kono\u00a0K, Kinowaki\u00a0K, Takazawa\u00a0Y, Takemura\u00a0T, Ubara\u00a0Y (2024) Histologically Proven Recurrent Synovitis after Nivolumab Treatment. Intern Med 63(6):867\u2013871","journal-title":"Intern Med"},{"key":"5480_CR10","first-page":"2012","volume":"28","author":"B Nijsse","year":"2012","unstructured":"Nijsse\u00a0B, Roks\u00a0G (2012) Carpal tunnel syndrome caused by remitting seronegative symmetrical synovitis with pitting oedema. BMJ Case Rep 28:2012","journal-title":"BMJ Case Rep"},{"key":"5480_CR11","doi-asserted-by":"crossref","unstructured":"Okuma K, Furuhata R, Kiyota Y, Kono A, Hayashi T, Kamata Y, Morioka H (2020) Acute progressive bilateral carpal tunnel syndrome associated with remitting seronegative symmetrical synovitis with pitting edema syndrome: A\u00a0case report. J\u00a0Orthop Surg 28(1)","DOI":"10.1177\/2309499019893079"},{"issue":"6","key":"5480_CR12","first-page":"e40145","volume":"15","author":"AE Omole","year":"2023","unstructured":"Omole\u00a0AE, Awosika\u00a0A, Khan\u00a0A, Adabanya\u00a0U, Anand\u00a0N, Patel\u00a0T, Edmondson\u00a0CK, Fakoya\u00a0AO, Millis\u00a0RM (2023) An Integrated Review of Carpal Tunnel Syndrome: New Insights to an Old Problem. Cureus 15(6):e40145","journal-title":"Cureus"},{"issue":"12","key":"5480_CR13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00115-021-01223-9","volume":"92","author":"M Renovanz","year":"2021","unstructured":"Renovanz\u00a0M, Rieger\u00a0J, Tabatabai\u00a0G (2021) Tumortherapieassoziierte neurologische Symptome. Nervenarzt 92(12):1305\u20131314","journal-title":"Nervenarzt"},{"issue":"5","key":"5480_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3899\/jrheum.2023-0969","volume":"51","author":"A Rouhi","year":"2024","unstructured":"Rouhi\u00a0A, Jamal\u00a0S, Arreola\u00a0LG, Moon\u00a0D, Hudson\u00a0M, Roberts\u00a0J, Ladouceur\u00a0A, Ye\u00a0C (2024) Immune Checkpoint Inhibitor-Associated Remitting Seronegative Symmetrical Synovitis With Pitting Edema: Description of a\u00a0New Entity by CanRIO. J\u00a0Rheumatol 51(5):523\u2013528","journal-title":"J Rheumatol"},{"issue":"11","key":"5480_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.23958\/ijirms\/vol05-i11\/981","volume":"5","author":"W Shalata","year":"2020","unstructured":"Shalata\u00a0W, Yakobson\u00a0A, Massalha\u00a0I, Grinberg\u00a0RD, Goldstein\u00a0IM, Gibbs\u00a0R, Rouvinov\u00a0K (2020) Carpal Tunnel Syndrome as an Unusual Immune Checkpoint Inhibitor Adverse Effect: A\u00a0Case Series and Review of the Literature. Int J Innov Res Med Sci 5(11):550\u2013553","journal-title":"Int J Innov Res Med Sci"},{"issue":"1","key":"5480_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/10781552231167559","volume":"30","author":"LB Shields","year":"2024","unstructured":"Shields\u00a0LB, Iyer\u00a0VG, Zhang\u00a0YP, Shields\u00a0CB (2024) Anti-cancer therapeutic agents and carpal tunnel syndrome: Clinical, electrodiagnostic, and ultrasound findings in seven patients. J\u00a0Oncol Pharm Pract 30(1):38\u201345","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"5480_CR17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/biomedicines12061319","volume":"12","author":"S De Stavropoulou Lorenzo","year":"2024","unstructured":"De Stavropoulou Lorenzo\u00a0S, Andravizou\u00a0A, Alexopoulos\u00a0H, Michailidou\u00a0I, Bokas\u00a0A, Kesidou\u00a0E, Boziki\u00a0MK, Parissis\u00a0D, Bakirtzis\u00a0C, Grigoriadis\u00a0N (2024) Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors. Biomedicines 12(6):1319","journal-title":"Biomedicines"},{"issue":"1","key":"5480_CR18","first-page":"52","volume":"110","author":"J Wipperman","year":"2024","unstructured":"Wipperman\u00a0J, Penny\u00a0ML (2024) Carpal Tunnel Syndrome: Rapid Evidence Review. Am Fam Physician 110(1):52\u201357","journal-title":"Am Fam Physician"},{"issue":"9","key":"5480_CR19","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/jpm13091340","volume":"13","author":"A Yakobson","year":"2023","unstructured":"Yakobson\u00a0A, Rouvinov\u00a0K, Cohen\u00a0AY, Goldstein\u00a0I, Saleh\u00a0AO, Solomon\u00a0A, Dudnik\u00a0Y, Shalata\u00a0W (2023) Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors. J\u00a0Pers Med 13(9):1340","journal-title":"J Pers Med"},{"issue":"4","key":"5480_CR20","first-page":"501","volume":"17","author":"F Zammit","year":"2024","unstructured":"Zammit\u00a0F, Seront\u00a0E (2024) Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A\u00a0Practical Review. Pharm 17(4):501","journal-title":"Pharm"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05480-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-025-05480-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05480-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T13:44:42Z","timestamp":1748439882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-025-05480-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["5480"],"URL":"https:\/\/doi.org\/10.1007\/s00105-025-05480-6","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"25 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Weyer-Fahlbusch, M.\u00a0Sandersfeld, C.\u00a0Ritthaler, L.\u00a0Hauck, P.\u00a0D\u00fccker, L.\u00a0Susok und T.\u00a0Gambichler geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}